Long-term use of MAO-B inhibitors in patients in the mid-stages of PD led to a significant reduction in levodopa requirements and lower frequency of dyskinesias, independently of which MAO-B inhibitor was administered, selegiline or rasagiline. The gene discussed is MAOB; the disease is drug-induced dyskinesia.